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ABSTRACT
Purpose: To evaluate 5-year results of escalated hyperfractionation schedule in aspect of local tumour control
(LTC) and late radiation toxicity.
Material and methods: Forty eight patients with squamous cell carcinoma of oral cavity (34 pts), oropharynx (11
pts) and larynx (3) in stage T1-4NO-1 have been treated at Centre of Oncology in Gliwice, between the years
1988-92. There were four patients with T1 primary tumour, 27 with T2, 11 with T3 and 2 with T4; in 4 patients the
tumour stage remains unknown (TX). All the patients were treated by radiation therapy alone, using the technique
of two opposed parallel fields and hyperfractionation with escalation of the dose per fraction during the second
part of the treatment schedule. The total dose ranged between 62,2 and 74 Gy. The median follow-up was 62
months.
Results: Despite of the relative high proportion of complete local regressions (75%), the 5-year LTC rate of 54%
was noted in the whole group of patients. Stage-related LTC rates were as follows: 100% for TX tumours, 50% for
T1, 55% for T2, 45% for T3 and 0% for T4. Acute radiation reactions were more intensive than those usually
observed during conventional radiotherapy; all patients experienced a confluent mucositis and two waves of
acute mucosal reaction because of treatment gap were observed during the radiation course. Severe late
radiation toxicity (grade IV) was noted in two patients (4%).
Conclusions: Long-term tumour control results of escalated hyperfractionation radiotherapy may suggest that
there is no benefit of a such regimen. However, in the majority of patients the treatment course differed markedly
from protocol assumptions.
INTRODUCTION
Accelerated repopulation of tumour c1onogen
during radiotherapy is recognized as an important
determinant of tumour control probability. In the
late 80s, it was postulated. that tumour clonogen
proliferation accelerates after 3-4 weeks from the
begining of radiation treatment at least in the
head and neck tumours and that the second part
of irradiation could be especially unsafe in regard
to the treatment breaks (Withers et aI., 1988).
Therefore, in some institutions so called
"escalating-dose regimens" of radiation treatment
were implemented, where the daily tumour dose
was progressively escalated during the course of
treatment (Harari et al. 1992, Kajanti et al. 1997,
Schwade et al. 1992, Maciejewski et al. 1992).
The rationale for this approach proposed in
Gliwice in 1988 was to counterbalance tumour
repopulation kinetics illustrated by the dog-leg
curve of the dose-time relationship.
Consequently, a new fractionation schedule was
designed: the treatment was divided into two
parts of irradiation, separated by a rest period.
The first part - hyperfractionation two times daily
of 1,6 Gy up to 32 Gy was followed after 7 days
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of a treatment gap by the second part, delivered
by an escalated fraction dose, starting from 1,5
Gy to 2,0 Gy also twice daily.
In this approach the overall treatment time
was reduced by about 1,5 - 2 weeks compared
with standard fractionation of 2 Gy per day, five
times per week.
The aim of this study was to estimate the
effectiveness of such a scheme in view of the
long-term tumour control and radiation toxicity.
MATERIAL AND METHODS
Between 1988 and 1992, at the Centre
Oncology Maria Sklodowska-Curie Memorial
Institute in Gliwice, 48 patients with squamous
cell cancer of the head and neck were treated
with escalated hyperfractionation regimen of
radiotherapy.
The study included 44 men and 4 women
(mean age - 55 years, range 41-75) with good
performance status (ZUBROD 0-1). Their red
blood cells counts and haemoglobin levels were
within the normal range.
Thirty four patients (71 %) had oral cavity cancer,
mainly in T2 and T3 stage. In 11 patients (23%)
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the tumour was located in the oropharynx, and
in three patients (6%) in the larynx. Only 8% of
patients had metastases to the single ipsilateral
neck node (tab. 1).
Oral cavity Oropharynx Larynx
T-stage 34 11 3
T1 4 - -
T2 18 6 3
T3 10 1 -
T4 2 - -
Tx - 4 -
N1 2 2 -
Table 1. Location and the TN stage
All patients were treated by radiotherapy alone
(only one received single course of
chemotherapy before irradiation).
Borders of irradiated fields were painted directly
on the skin of the head and neck and a
customized system - was used for the
immobilization of patients' head during irradiation.
The treatment plan consisted of two courses of
irradiation. The planned total dose depended on
the tumour stage, and ranged from 66 to 74Gy.
The fraction dose of 1.6 Gy in the first part of the
treatment was given by BiD regimen with a 6 h
interval, 5 days a week up to the dose of 32Gy.
Assuming that the dose intensity of 2,29 Gy/day
during the first two weeks of treatment would
produce a severe acute mucosal effect, one
week of a planned rest period was introduced
before dose escalation in the second part of
irradiation.
After the planned gap the dose per fraction,
also given BiD, was escalated every two days
by 0.1 Gy, starting from 1.5Gy to 2Gy (fig. 1).
All patients were treated with a cobalt unit
using a technique of two opposed parallel fields.
After reducting the treatment volume (exclusion
of the spinal cord) electron irradiation to the
posterior cervical nodes was supplemented. Off-
cord reduction fields were introduced after the
dose in the range between 38 and 44,4 Gy.
The grade of severity of the acute mucosal
reaction during the treatment was scored
according to the multipunctual European system
proposed by Dische et al. (1988, 1989). This
system places more emphasis on functional
radiation effects, such' as dysphagia and
odynophagia than on morphological changes
(like the EORTC/RTOG system). The former
symptoms are highly subjective - varying from
patient to patient (e.g. mucositis) in spite of the
same score according to the EORTC/RTOG
score. The details of the Dische system were
described elsewhere (Dische 1988, 1989,
Maciejewski 1991).
RESULTS
The average total dose was 68,6 Gy, and it
ranged from 62,2 to 74 Gy.
The radiation treatment was completed in 46
patients (96%). Two patients did not complete
the treatment because of severe acute mucosal
reaction. Intolerance of acute reaction was the
reason of the planned gap prolongation in 80%
of patients - the mean gap-time being 13 days
and ranging from 7 to 25 days. This extended
the range of the overall treatment time (On)
from 33 to 53 days (median: 39 days).
Only two patients did not reqUire supportive
treatment with corticosteroids, antibiotics,
analgetics and parenteral supplement of liquids.
PART II
3,0 3,2 3,4 3,6 3,8 4,0 Gy3,2
Total dose: 66,0 - 74,0 Gy
Irradiation - twice a day
Dose per fraction:
Fig. 1 Scheme of fractionation
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Complete tumour response (CR) scored directly
after completing the irradiation was observed in
75% of patients. Regression rates depending
on the tumour site and stage are presented in
table 2.
Location of tumour No %
oral cavity 24/34 71
oropharynx 9/11 82
larynx 3/3 100
Tumour stage
T1 4 100
T2 23/27 85
T3 5/11 45
T4 0/2 0
Tx 4/4 100
Table 2. Complete tumour regression - location and T-stage
For the oral cavity cancers (the largest group of
cases), the local tumour control rate was equal to
disease free survival and ranged from 50% for
T1, 44% for T2 to 40% for T3 tumours. (Fig. 5)
Local tumour control for T1 tumours was
slightly lower than that for T2 tumours: by only
50% and 55% respectively, whereas for Tx it
was even 100%. However, the number of
patients with T1 and Tx tumours was only 8 (T1-
4, TX-4), therefore the results for T1, T2 and Tx
tumours are presented further on one curve.
The five-year local tumour control for T3
tumours was 45% (Fig. 4). No patient with T4
tumour lived longer than 6 months
The five-year disease free survival for the
whole group of patients was 48%
(Fig. 2) and the 5-year local tumour control rate
was 54% (Fig 3).
I I I I I I I I I
90 - - - -+ - - - -l - - - -1- - - - I- - - - ~ - - - -l - - - -1- - - - I- - - - + - - -
I I I I I I I I I80 - - _ .L .J 1 L .1 J 1 L .L _
I I I I I I I I J
;~ ~~t~~~t~~~1~ ~~j~~~~i~ ~~~t~~ ~t~ ~~
I I I I
50 - - - -+ - - - -t - - -1- - - I- - - - -t - - - -\ - - - I~ - - - ::t: - - -
I I I I I I I40 - - _.1 .J 1 L .1 .J 1 L J. _
I I I I I I I I 1
30 - - - +- - - ~ - - - -:- - - - ~ -- -1- - - ~ - - - -;- - - - ~ - - -+- - -
~ ---~---~----:----~---~---~----~---~---~---
I I I I I I I I I
10 - - - + - - - -l - - - -1- - - - I- - - - ... - - - -l - - - -1- - - - I- - - - + - - -
I I I I I I I I I
0-1-----1--+---+--+--1---+---+--+---1---1
o 6 12 18 24 30 36 42 48 54 60
months
Fig 2. 5-year disease free survival
100 .,------,--r---,--,----,----,----.--..,---,----.
I I I I I I I t I90 - - - J. J L 1. ..J 1 L ..1 1 _
I I I I I I I I I
~ ---+---~----~---}---~----:----~---~---~----
:: ~~:~~~~t~~~j~~~t~ ~ ~t ~~~i ~ ~ ~~j~~~~
, ,
50 - - - ... - - - --I - - - -1- - - - .j.. - - - -I - - - -1- - - - I- - - - of - - - -1- - - -
I I l I 1 I I I 1
40 - - - +-- - -:- - - -:- - - - f- - - - ~ - - - -;- - - - ~ - - - +- - - -:- - --
I I 1 1 I I I t I
30 --- +-- ---1-- --1-- - -+---- -1-.---1----1- ---of-- - -1- - --
I t I I I I I I \
20 - - - +- - - -: - - - -:- - - - r---~ ----:- ---r---1- - - -: - - - -
I I lit I I I I
10 - - - ... - - - --j - - - -1- - - - t- - - - -1 - - - -1- - - - t" - - - -t - - - -I - - - -
I I 1 I I 1 I 1 1o I • t I I 1 1 • •
o 6 12 18 24 30 36 42 48 54 60
months
Fig 3. 5-year local tumour control
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DISCUSSION
Fig. 6. Mean reactions during escalated hyperfractionation.
Fig. 5. 5-year local tumour control and disease free survival
for oral cavity tumours - T-stage.
Severe (grade IV) late reactions were observed
in two patients as necroses of the mandibula.
Both patients had cancer of the oral cavity and
received the total dose higher than 70Gy. Seven
month after completing irradiation one of them
had teeth extraction.
No other serious complications were observed.
Two main justifications for the introduction of
escalated hyperfractionation into the
radiotherapy clinical practice was proposed:
escalation of the daily dose during
radiotherapy should counterbalance tumour
repopulation as treatment progresses,
increasing total tumour cell kill effect and in
consequence, giving better results of irradiation,
- less intensive therapy at the beginning of
irradiation and a rest period will stimulate rapid
proliferation of normal mucosal stem cells, and
the patients will probably tolerate better the
more intensive irradiation as it progresses.
Four reports concerning escalated
hyperfractionation radiotherapy for the head and
neck cancer have been published so far (Harari
et al. 1992, Kajanti et al. 1997, Maciejewski et
al. 1992, Schwade et al. 1992). All of them are
brief, preliminary reports and comprise small
groups of patients only. Complete tumour
regression after completing irradiation ranged
from 83 to 93%, which was interpreted as an
optimistic prognostic factor. Severe acute
reactions during the treatment course were
defined as "tolerable", but they were always
more severe than those observed during
conventional fractionation.
In 1997 Kajanti at al. presented more long-
term (3-year) results of irradiation of 29 patients
with head and neck cancers in stage III-IV.
Complete tumour response at 3 months after
radiotherapy was 93%, but the local tumour
control dropped after 3 years to 60%. All the
patients developed acute mucosal reactions
which were completely healed. In 52% of
patients hospitalization was needed mainly
because of nutritional support, but finally, no
serious late complications were observed.
No other long-term reports on escalated
fractionation have been published as yet,
therefore our results should be compared only
with a Finnish study. In this study, authors
observed a similar tumour control rates, Le. 60%
(Kajanti et aI., 1997) versus 54% in our study.
However, our results were concerned mainly
with the patients in stage II, whereas in the
Finnish study more advanced tumours (stage III
and IV) were registered. That is why they had to
be given higher total doses of 74 Gy in
comparision with 69 Gy in Gliwice. Also in the
Finnish study, two-thirds of the patients received
the prescribed dose within the planned OTT. In
our study, only 20% of cases completed the
treatment according to the planned gap duration.
We can state that our study did not show any
benefit from the escalated hyperfractionation
regime, and the results are comparable with
those of a similar historical group treated by
[3T1__ T2
-A-T3
An interesting observation is that among 36
pts with CR (75%), 8 (22%) patients
experienced local recurrence early after the end
of the treatment, that is up to 15 months. There
were no local recurrences observed during the
follow-up exceeding this period (Fig. 3).
All the patients developed confluent mucositis
during the radiation course, which was more
intensive than that usually observed during
conventional fractionation.
During the first partof irradiation the mucosal
reaction was elevated up to the level of
confluent mucositis covering more than 50% of
the irradiated mucosa.
Tolerance of the second, escalated part of
treatment was better than the first one, mainly
because of the partial healing of mucous
membrane during the gap period (Fig. 6). This
acute mucosal toxicity was previously described
in detail by Maciejewski et al (1991, 1992).
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conventional fractionation at our department
(Maciejewski et ai, 1989). This is especially
surprising as regards the expected high
probability of tumour cure estimated for those
schedules (Fowler et ai, 1992).
In our opinion, the observed lack of treatment
benefit can a be result of the following factors:
1) treatment rest period
Before begining the study it was assumed that
the duration of the planned gap should be only
one week. Because of severe confluent
mucositis that appeared during the week of on
(it was earlier and much more severe than that
usually observed in standard irradiation), the
planned gap had to be extended almost twice.
Assuming that the tumour clonogen repopulaion
"kicks-on" from the beginning of the third week
of on (Fowler, 1992), it may be that during the
long treatment gap period the lethal effect of the
first part of irradiation could have been markedly
lost by tumour tumour regeneration.
Kajanti et al. also observed the detrimental
effect of treatment time prolongation in their
escalated study. None of 10 patients who had
longer on was cured in comparision with only
two out of the 19 patients who received the
prescribed dose within the planned time.
Also Wang et al. in their work based on the
clinical experience with MGH BID program
(hyperfractionated, accelerated schedule
somewhat similar to escalated one), point out
the deletorious effect of prolonged treatment
course as a result of tumour clonogen
repopulation which occured during the gap
period (Wang et aI., 1996).
The importance of treatment gaps for
radiotherapy outcome was also investigated by
Skladowski et al. (1994). They observed that gaps
prior to Day-19, and after Day-29 of on during
the irradiation of the supraglottic cancer were
associated with a lower tumour control probability
than the gaps in the middle period of treatment
(Le. between Day-20 and Day-28 of On).
The radiobiological explanation of this "gap-
position" phenomenon remains unknown,
however several possible effects could play a
role and result in tumour regeneration
(Skladowski, 1996).
The "gap-position" phenomenon has recently
been confirmed for all head and neck squamous
cell cancers (Skladowski et aI., 1998) in a
retrospective data set of 2612 patients, and in a
view of that, our lower than expected, results
could also find some explanation.
The rest period in the escalated regime always
began on Day-13 of the on, thus within the
most "unsafe" time for treatment interruption
(Skladowski, 1994, 1998).
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2) hazard of geographical miss during the
second part of treatment
In the present study, patients were irradiated
without stabilization by aquaplast masks, and
borders of the irradiated portals were marked
directly on the skin. In some patients during the
rest period, border lines became effaced and the
portals had to be resimulated at the begining of
the second (escalated) part of treatment. It was
noticed that in those patients radiation fields
were reduced on average by 10% of the total
area in comparison with the area of the initial
fields. The shrinkage of the tumour observed
after the first part of the irradiation and rest
period may have led the physicians to
unintentionally decrease the treatment volume in
the second part of the irradiation. Thus, it seems
that the incorrect delineation of the primary
tumour could an important role in the influence
of treatment outcome of escalated irradiation.
Finally, due to the several factors described
above we are led to the conclusion that some
inconsistencies in the radiation treatment do not
enable us to determine objectivly clinical
effectiveness of the escalated fractionation
schedule.
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